NEW YORK - Aspire Biopharma, Inc., a biopharmaceutical technology company, and PowerUp Acquisition Corp. (Nasdaq: PWUP), a special purpose acquisition company, have announced a definitive merger agreement. The transaction values Aspire at a pre-money equity value of approximately $316 million.
Aspire, founded in 2021 and headquartered in Humacao, Puerto Rico, specializes in developing novel delivery mechanisms for FDA-approved drugs, nutraceuticals, and supplements. Its patented and patent-pending delivery system is designed for rapid sublingual absorption, bypassing the gastrointestinal tract to reduce liver toxicity.
The anticipated proceeds from the merger are expected to accelerate Aspire's strategic growth and development of its pipeline, including Instaprin™, a soluble, pH-neutral aspirin intended for emergencies and pain management. Aspire plans to file a 505(b)(2) New Drug Application with the FDA for Instaprin™.
The combined entity, to be named Aspire Biopharma Holdings, Inc., plans to list on Nasdaq under the ticker symbol "ASPH", subject to regulatory and stockholder approvals. The business combination is projected to close by the end of Q4 2024 or early Q1 2025.
Kraig Higginson, CEO of Aspire, emphasized the significance of the merger for the company's growth and upcoming product launches. Suren Ajjarapu, CEO of PowerUp, highlighted Aspire's innovative technology and market potential as key reasons for the partnership.
The boards of directors of both companies have approved the merger, pending stockholder votes and other customary closing conditions. Post-merger, Aspire's existing shareholders will retain a majority stake in the new company.
The transaction is expected to enable Aspire to expand its product offerings and forge strategic partnerships, including advancing Instaprin™ through regulatory processes.
Legal counsel for the merger includes Dykema Gossett PLLC for PowerUp and Sichenzia Ross Ference Carmel LLP for Aspire Biopharma.
This news article is based on a press release statement and does not contain all information concerning the business combination. It is not intended as an offer or solicitation for the purchase of securities.
In other recent news, Aspire Biopharma, an early-stage biopharmaceutical company, has announced its intention to merge with PowerUp Acquisition Corp., a special purpose acquisition company. The merger is aimed at listing the combined entity on a national securities exchange. The company's lead product, Instaprin™, a fast-acting, pH-neutral aspirin formulation, is expected to be submitted for FDA approval under the 505(b)(2) regulatory pathway. Aspire is also developing a range of other pharmaceutical and nutraceutical products, expanding its patent portfolio internationally. The CEOs of both Aspire and PowerUp have expressed optimism about the merger, citing enhanced visibility, access to capital, and potential growth opportunities for investors. However, the transaction is yet to be finalized and is subject to various approvals. These are some of the recent developments in the company.
InvestingPro Insights
PowerUp Acquisition Corp. (Nasdaq: PWUP) is making strategic moves with its definitive merger agreement with Aspire Biopharma, Inc., but what does the data say about PowerUp's current financial health and market performance? According to InvestingPro data, PowerUp's market capitalization stands at a modest $87.2 million, reflecting the size and scale of the company within the biopharmaceutical technology sector.
InvestingPro Tips suggest that management at PowerUp has been actively engaging in share buybacks, a move that can often signal confidence in the company's future prospects. However, a noteworthy point for investors is the company's current overbought status as indicated by the Relative Strength Index (RSI), which could suggest a potential pullback in stock price. Moreover, PowerUp does not offer a dividend, which may influence the investment decisions of income-focused shareholders.
From a financial perspective, PowerUp has been navigating through challenges, as reflected in the negative P/E ratio of -39.31 and the adjusted figure of -26.51 for the last twelve months as of Q2 2024. This indicates that the company has not been profitable over the past year. Additionally, the company's short-term obligations exceed its liquid assets, which could present liquidity risks.
Investors considering the merger's potential should also note PowerUp's stock price behavior, which tends to move inversely to market trends, and its low price volatility, which could offer some stability amidst market fluctuations. With the next earnings date set for September 4, 2024, market watchers and potential investors will be keen to see how the merger impacts PowerUp's financials going forward.
For a deeper dive into PowerUp's performance and additional InvestingPro Tips, interested parties can explore further at https://www.investing.com/pro/PWUP, where more than six additional tips are available to help gauge the investment potential of PowerUp Acquisition Corp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.